{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:06:22Z","timestamp":1784167582547,"version":"3.55.0"},"reference-count":27,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>M-type phospholipase A2 receptor (PLA2R) is the major autoantigen of membranous nephropathy (MN). As the specific antibodies of MN, the correlation between serum PLA2R antibody (sPLA2R-Ab) levels and PLA2R-associated MN (PMN) risk stratification is still controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To apply the time-resolved fluorescence immunoassay (TRFIA) method on urine PLA2R-Ab (uPLA2R-Ab), detect, and then establish a more sensitive method of combined serum and urine PLA2R-Ab detection for PMN hazard stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>A highly sensitive TRFIA method was used to detect the initial serum and urine samples of patients with PMN. Patients were grouped into remission and nonremission groups according to the outcomes after 12 months of treatment and the data were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>The cutoff values of sPLA2R-IgG (sPLA2R\u2013immunoglobulin G), uPLA2R-IgG, sPLA2R-IgG4, and uPLA2R-IgG4 for distinguishing between remission and nonremission groups were 50 relative units (RU)\/mL, 3.51 RU\/mL, 6835 ng\/mL, and 143.4 ng\/mL, respectively. The average value in the remission group for sPLA2R-IgG, uPLA2R-IgG, sPLA2R-IgG4, and uPLA2R-IgG4 was 37.39 RU\/mL, 1.10 RU\/mL, 3498.99 ng\/mL, and 33.83 ng\/mL, respectively. The average value in the nonremission group for sPLA2R-IgG, uPLA2R-IgG, sPLA2R-IgG4, and uPLA2R-IgG4 was 279.96 RU\/mL, 45.36 RU\/mL, 25762.47 ng\/mL, and 1383.89 ng\/mL, respectively. For sPLA2R-Ab as the primary factor, in combination with uPLA2R-Ab, the high-risk predictive value of combined detection of serum and urine PLA2R-IgG and of serum and urine PLA2R-IgG4 was upgraded from 54.55% to 100% and from 75% to 100%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>A highly sensitive TRFIA method was applied in this study; the combined detection of serum and urine PLA2R-Ab improves the efficiency of PMN risk stratification, and can provide a better assessment of PMN monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2024-0161-oa","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:18:25Z","timestamp":1732857505000},"page":"e151-e159","source":"Crossref","is-referenced-by-count":3,"title":["Urine PLA2R Antibody Detection in Hazard Stratification of PLA2R-Associated Membranous Nephropathy"],"prefix":"10.5858","volume":"149","author":[{"given":"Tianyu","family":"Zheng","sequence":"first","affiliation":[{"name":"From College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China (Zheng, Qin, Hui, Z Zhou, Fu, X Zhou, Zhao, Huang)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qin","sequence":"additional","affiliation":[{"name":"From College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China (Zheng, Qin, Hui, Z Zhou, Fu, X Zhou, Zhao, Huang)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanli","family":"Tang","sequence":"additional","affiliation":[{"name":"The Department of Nephrology (Key Laboratory of Kidney Disease Prevention and Control Technology), Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China (Tang, Bi, Du)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Bi","sequence":"additional","affiliation":[{"name":"The Department of Nephrology (Key Laboratory of Kidney Disease Prevention and Control Technology), Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China (Tang, Bi, Du)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxiang","family":"Hui","sequence":"additional","affiliation":[{"name":"From College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China (Zheng, Qin, Hui, Z Zhou, Fu, X Zhou, Zhao, Huang)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"From College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China (Zheng, Qin, Hui, Z Zhou, Fu, X Zhou, Zhao, Huang)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Fu","sequence":"additional","affiliation":[{"name":"From College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China (Zheng, Qin, Hui, Z Zhou, Fu, X Zhou, Zhao, Huang)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Sheng","sequence":"additional","affiliation":[{"name":"Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (Sheng)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Zhou","sequence":"additional","affiliation":[{"name":"From College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China (Zheng, Qin, Hui, Z Zhou, Fu, X Zhou, Zhao, Huang)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Zhao","sequence":"additional","affiliation":[{"name":"From College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China (Zheng, Qin, Hui, Z Zhou, Fu, X Zhou, Zhao, Huang)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Du","sequence":"additional","affiliation":[{"name":"The Department of Nephrology (Key Laboratory of Kidney Disease Prevention and Control Technology), Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China (Tang, Bi, Du)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[{"name":"The Department of Nephrology, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China (He)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Huang","sequence":"additional","affiliation":[{"name":"From College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China (Zheng, Qin, Hui, Z Zhou, Fu, X Zhou, Zhao, Huang)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"key":"i1543-2165-149-7-e151-b01","series-title":"Front Immunol","first-page":"1809","article-title":"Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role","volume":"10","author":"Liu","year":"2019","unstructured":"Liu\n              W\n            ,\nGaoC,\nDaiH, et al.\n          Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role. Front Immunol. 2019;10:1809. doi:10.3389\/fimmu.2019.01809"},{"issue":"12","key":"i1543-2165-149-7-e151-b02","series-title":"Kidney Int","first-page":"2131","article-title":"The podocyte\u2019s response to injury: role in proteinuria and glomerulosclerosis","volume":"69","author":"Shankland","year":"2006","unstructured":"Shankland\n              SJ.\n            \n          \n          The podocyte\u2019s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69(12):2131\u20132147. doi:10.1038\/sj.ki.5000410"},{"issue":"6","key":"i1543-2165-149-7-e151-b03","series-title":"Kidney Int","first-page":"1092","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","unstructured":"Sethi\n              S\n            ,\nBeckLHJr,GlassockRJ, et al.\n          Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int. 2023;104(6):1092\u20131102. doi:10.1016\/j.kint.2023.06.032"},{"issue":"1","key":"i1543-2165-149-7-e151-b04","series-title":"N Engl J Med","first-page":"11","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","unstructured":"Beck\n              LH\n              Jr,\n            \n            \n              Bonegio\n              RG\n            ,\nLambeauG, et al.\n          M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321. doi:10.1056\/NEJMoa0810457"},{"key":"i1543-2165-149-7-e151-b05","series-title":"J Immunol Res","first-page":"143274","article-title":"Antiphospholipase A2 receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy","volume":"2014","author":"Behnert","year":"2014","unstructured":"Behnert\n              A\n            ,\nSchifferM,\nM\u00fcller-DeileJ,\nBeckLHJr,MahlerM,\nFritzlerMJ.\n          Antiphospholipase A2 receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy. J Immunol Res. 2014;2014:143274. doi:10.1155\/2014\/143274"},{"issue":"2","key":"i1543-2165-149-7-e151-b06","series-title":"Clin Chem Lab Med","first-page":"251","article-title":"Quantitative detection of anti-PLA2R antibodies targeting different epitopes and its clinical application in primary membranous nephropathy","volume":"61","author":"Qin","year":"2022","unstructured":"Qin\n              Y\n            ,\nWuQ,\nShengH, et al.\n          Quantitative detection of anti-PLA2R antibodies targeting different epitopes and its clinical application in primary membranous nephropathy. Clin Chem Lab Med. 2022;61(2):251\u2013259. doi:10.1515\/cclm-2022-0720"},{"issue":"1","key":"i1543-2165-149-7-e151-b07","series-title":"J Am Soc Nephrol","first-page":"197","article-title":"Clinical relevance of domain-specific phospholipase A(2) receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","unstructured":"Reinhard\n              L\n            ,\nZahnerG,\nMenzelS,\nKoch-NolteF,\nStahlRAK,\nHoxhaE.\n          Clinical relevance of domain-specific phospholipase A(2) receptor 1 antibody levels in patients with membranous nephropathy. J Am Soc Nephrol. 2020;31(1):197\u2013207. doi:10.1681\/asn.2019030273"},{"issue":"1","key":"i1543-2165-149-7-e151-b08","series-title":"Clin Exp Immunol","first-page":"57","article-title":"Distribution of IgG subclasses in membranous nephropathy","volume":"58","author":"Doi","year":"1984","unstructured":"Doi\n              T\n            ,\nMayumiM,\nKanatsuK,\nSuehiroF,\nHamashimaY.\n          Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol. 1984;58(1):57\u201362."},{"issue":"11","key":"i1543-2165-149-7-e151-b09","series-title":"Intern Med","first-page":"936","article-title":"Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy","volume":"41","author":"Kuroki","year":"2002","unstructured":"Kuroki\n              A\n            ,\nShibataT,\nHondaH,\nTotsukaD,\nKobayashiK,\nSugisakiT.\n          Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002;41(11):936\u2013942. doi:10.2169\/internalmedicine.41.936"},{"key":"i1543-2165-149-7-e151-b10","series-title":"Clin Biochem","first-page":"49","article-title":"Establishment and application of an immunoassay for the simultaneous detection of IgG and its subtype IgG4 autoantibodies against M-type phospholipase A2 receptor","volume":"96","author":"Li","year":"2021","unstructured":"Li\n              T\n            ,\nWuQ,\nYangX, et al.\n          Establishment and application of an immunoassay for the simultaneous detection of IgG and its subtype IgG4 autoantibodies against M-type phospholipase A2 receptor. Clin Biochem. 2021;96:49\u201355. doi:10.1016\/j.clinbiochem.2021.07.006"},{"issue":"4","key":"i1543-2165-149-7-e151-b11","series-title":"Kidney Blood Press Res","first-page":"848","article-title":"Phospholipase A2 receptor antibody IgG4 subclass improves sensitivity and specificity in the diagnosis of idiopathic membranous nephropathy","volume":"44","author":"Huang","year":"2019","unstructured":"Huang\n              B\n            ,\nZhangY,\nWangL, et al.\n          Phospholipase A2 receptor antibody IgG4 subclass improves sensitivity and specificity in the diagnosis of idiopathic membranous nephropathy. Kidney Blood Press Res. 2019;44(4):848\u2013857. doi:10.1159\/000500456"},{"key":"i1543-2165-149-7-e151-b12","series-title":"PeerJ","first-page":"e14193","article-title":"PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study","volume":"10","author":"Huang","year":"2022","unstructured":"Huang\n              Y\n            ,\nZhouJ,\nZhouK, et al.\n          PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study. PeerJ. 2022;10:e14193. doi:10.7717\/peerj.14193"},{"issue":"6","key":"i1543-2165-149-7-e151-b13","series-title":"Ann Clin Lab Sci","first-page":"777","article-title":"Lower serum and higher urine immunoglobulin G are associated with an increased severity of idiopathic membranous nephropathy","volume":"49","author":"Hou","year":"2019","unstructured":"Hou\n              J\n            ,\nChengY,\nHouY,\nWuH.\n          Lower serum and higher urine immunoglobulin G are associated with an increased severity of idiopathic membranous nephropathy. Ann Clin Lab Sci. 2019;49(6):777\u2013784."},{"issue":"1","key":"i1543-2165-149-7-e151-b14","series-title":"BMC Nephrol","first-page":"313","article-title":"Complement activation products in the circulation and urine of primary membranous nephropathy","volume":"20","author":"Zhang","year":"2019","unstructured":"Zhang\n              MF\n            ,\nHuangJ,\nZhangYM, et al.\n          Complement activation products in the circulation and urine of primary membranous nephropathy. BMC Nephrol. 2019;20(1):313. doi:10.1186\/s12882-019-1509-5"},{"key":"i1543-2165-149-7-e151-b15","series-title":"Front Med (Lausanne)","first-page":"241","article-title":"Immune-monitoring disease activity in primary membranous nephropathy","volume":"6","author":"Cravedi","year":"2019","unstructured":"Cravedi\n              P\n            ,\nJarqueM,\nAngelettiA,\nFav\u00e0\u00c0,\nCantarelliC,\nBestardO.\n          Immune-monitoring disease activity in primary membranous nephropathy. Front Med (Lausanne). 2019;6:241. doi:10.3389\/fmed.2019.00241"},{"key":"i1543-2165-149-7-e151-b16","series-title":"Clin Immunol","first-page":"108976","article-title":"Revisiting immunological and clinical aspects of membranous nephropathy","volume":"237","author":"Nieto-Ga\u00f1\u00e1n","year":"2022","unstructured":"Nieto-Ga\u00f1\u00e1n\n              I\n            ,\nIturrieta-ZuazoI,\nRitaC,\nCarrasco-Sayalero\u00c1.\n          Revisiting immunological and clinical aspects of membranous nephropathy. Clin Immunol. 2022;237:108976. doi:10.1016\/j.clim.2022.108976"},{"issue":"1","key":"i1543-2165-149-7-e151-b17","series-title":"Oncotarget","first-page":"67","article-title":"Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy","volume":"9","author":"Wang","year":"2018","unstructured":"Wang\n              Y\n            ,\nHeYX,\nDiaoTT, et al.\n          Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy. Oncotarget. 2018;9(1):67\u201374. doi:10.18632\/oncotarget.19859"},{"key":"i1543-2165-149-7-e151-b18","series-title":"Sci Rep","first-page":"46096","article-title":"A novel time-resolved fluoroimmunoassay for the quantitative detection of antibodies against the phospholipase A2 receptor","volume":"7","author":"Huang","year":"2017","unstructured":"Huang\n              B\n            ,\nWangL,\nZhangY, et al.\n          A novel time-resolved fluoroimmunoassay for the quantitative detection of antibodies against the phospholipase A2 receptor. Sci Rep. 2017;7:46096. doi:10.1038\/srep46096"},{"issue":"4s","key":"i1543-2165-149-7-e151-b19","series-title":"Kidney Int","first-page":"S1","article-title":"2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"KDIGO","year":"2021","unstructured":"KDIGO\n          \n          2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4s):S1\u2013S276. doi:10.1016\/j.kint.2021.05.021"},{"issue":"1","key":"i1543-2165-149-7-e151-b20","series-title":"Am J Kidney Dis","first-page":"157","article-title":"The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey","volume":"56","author":"Glassock","year":"2010","unstructured":"Glassock\n              RJ.\n            \n          \n          The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010;56(1):157\u2013167. doi:10.1053\/j.ajkd.2010.01.008"},{"key":"i1543-2165-149-7-e151-b21","series-title":"Annu Rev Pathol","first-page":"287","article-title":"Molecular pathogenesis of membranous nephropathy","volume":"15","author":"Ronco","year":"2020","unstructured":"Ronco\n              P\n            ,\nDebiecH.\n          Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol. 2020;15:287\u2013313. doi:10.1146\/annurev-pathol-020117-043811"},{"issue":"6","key":"i1543-2165-149-7-e151-b22","series-title":"J Allergy Clin Immunol","first-page":"1988","article-title":"Improvement of idiopathic membranous nephropathy diagnosis with ultrasensitive quantitative detection of anti-phospholipase A2 receptor","volume":"139","author":"Huang","year":"2017","unstructured":"Huang\n              B\n            ,\nWangL,\nCaoYN, et al.\n          Improvement of idiopathic membranous nephropathy diagnosis with ultrasensitive quantitative detection of anti-phospholipase A2 receptor. J Allergy Clin Immunol. 2017;139(6):1988\u20131990.e2. doi:10.1016\/j.jaci.2016.10.020"},{"issue":"17","key":"i1543-2165-149-7-e151-b23","series-title":"N Engl J Med","first-page":"1050","article-title":"Anionic sites and the mechanisms of proteinuria","volume":"309","author":"Cotran","year":"1983","unstructured":"Cotran\n              RS\n            ,\nRennkeHG.\n          Anionic sites and the mechanisms of proteinuria. N Engl J Med. 1983;309(17):1050\u20131052. doi:10.1056\/nejm198310273091709"},{"issue":"1","key":"i1543-2165-149-7-e151-b24","series-title":"Clin Kidney J","first-page":"53","article-title":"Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy","volume":"7","author":"Bandak","year":"2014","unstructured":"Bandak\n              G\n            ,\nJonesBA,\nLiJ,\nYeeJ,\nUmanathK.\n          Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy. Clin Kidney J. 2014;7(1):53\u201356. doi:10.1093\/ckj\/sft152"},{"issue":"4","key":"i1543-2165-149-7-e151-b25","series-title":"Nephrol Dial Transplant","first-page":"498","article-title":"Altered IgG(4) renal clearance in patients with inflammatory bowel diseases: evidence for a subclinical impairment of protein charge renal selectivity","volume":"15","author":"Monteleone","year":"2000","unstructured":"Monteleone\n              G\n            ,\nCristinaG,\nParrelloT, et al.\n          Altered IgG(4) renal clearance in patients with inflammatory bowel diseases: evidence for a subclinical impairment of protein charge renal selectivity. Nephrol Dial Transplant. 2000;15(4):498\u2013501. doi:10.1093\/ndt\/15.4.498"},{"key":"i1543-2165-149-7-e151-b26","series-title":"Biomed Res Int","first-page":"9127520","article-title":"Clinical evaluation of antiphospholipase A2 receptor IgG4 level and its IgG4-to-IgG ratio based on quantitative immunoassays in idiopathic membranous nephropathy","volume":"2022","author":"Zhang","year":"2022","unstructured":"Zhang\n              Y\n            ,\nHuangY,\nHuangB, et al.\n          Clinical evaluation of antiphospholipase A2 receptor IgG4 level and its IgG4-to-IgG ratio based on quantitative immunoassays in idiopathic membranous nephropathy. Biomed Res Int. 2022;2022:9127520. doi:10.1155\/2022\/9127520"},{"issue":"4","key":"i1543-2165-149-7-e151-b27","series-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao","first-page":"579","article-title":"Clinical significance of IgG4 level in predicting the activity and outcome of phospholipase A2 receptor-associated membranous nephropathy [in Chinese]","volume":"44","author":"Du","year":"2022","unstructured":"Du\n              YY\n            ,\nJiangX,\nWangWR,\nTangXL,\nSunY.\n          Clinical significance of IgG4 level in predicting the activity and outcome of phospholipase A2 receptor-associated membranous nephropathy [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022;44(4):579\u2013584. doi:10.3881\/j.issn.1000-503X.14976"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/7\/article-pe151.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/7\/e151\/3527663\/i1543-2165-149-7-e151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/7\/article-pe151.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/7\/article-pe151.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:55:03Z","timestamp":1784166903000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/7\/article-pe151.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2024-0161-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}